



EMERGING IMMUNO-ONCOLOGY COMBINATIONS FOR THE TREATMENT OF HCC

Saturday 21 November 2020

12:00–13:30 (SGT), Channel 2

Chairperson and speaker: Stephen L. Chan

Speakers/panellists: Ignacio Melero, Ghassan Abou-Alfa, Choo Su Pin

Agenda

Duration

5 mins	Welcome and introduction	Stephen L. Chan (Hong Kong)
20 mins	Immune checkpoint molecules: key players in the pathogenesis of HCC	Ignacio Melero (Spain)
15 mins	Optimising the immune response: exploring high-dose priming with anti-CTLA-4 therapy in unresectable HCC	Stephen L. Chan (Hong Kong)
15 mins	Recent advances in the treatment of unresectable HCC	Ghassan Abou-Alfa (USA)
20 mins	Clinical experience in unresectable HCC	Choo Su Pin (Singapore)

Live Q&A

Join the discussion on Saturday 21 November 2020
13:15–13:30 (SGT)

This symposium is organised and funded by AstraZeneca
During this symposium, data may refer to medicines or indications under investigation or that may not be approved in your country
The information should under no circumstances be regarded as a recommendation for use of the medicine or indication
Please consult your local prescribing information

Veeva ID: CH-3207, Date of Preparation: October 2020